Suppr超能文献

大麻使用与慢性肾脏病:流行病学关联及孟德尔随机化

Cannabis Use and CKD: Epidemiological Associations and Mendelian Randomization.

作者信息

Dellepiane Sergio, Paranjpe Ishan, Rajagopal Madhumitha, Kamat Samir, O'Hagan Ross, Gulamali Faris, Rein Joshua L, Charney Alexander W, Do Ron, Coca Steven, Glicksberg Benjamin S, Nadkarni Girish N

机构信息

Mount Sinai Clinical Intelligence Center (MSCIC), Icahn School of Medicine at Mount Sinai, New York, NY.

Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Kidney Med. 2022 Dec 11;5(2):100582. doi: 10.1016/j.xkme.2022.100582. eCollection 2023 Feb.

Abstract

RATIONALE & OBJECTIVE: The association between cannabis use and chronic kidney disease (CKD) is controversial. We aimed to assess association of CKD with cannabis use in a large cohort study and then assess causality using Mendelian randomization with a genome-wide association study (GWAS).

STUDY DESIGN

Retrospective cohort study and genome-wide association study.

SETTING & PARTICIPANTS: The retrospective study was conducted on the All of Us cohort (N=223,354). Genetic instruments for cannabis use disorder were identified from 3 GWAS: the Psychiatric Genomics Consortium Substance Use Disorders, iPSYCH, and deCODE (N=384,032). Association between genetic instruments and CKD was investigated in the CKDGen GWAS (N > 1.2 million).

EXPOSURE

Cannabis consumption.

OUTCOMES

CKD outcomes included: cystatin-C and creatinine-based kidney function, proteinuria, and blood urea nitrogen.

ANALYTICAL APPROACH

We conducted association analyses to test for frequency of cannabis use and CKD. To evaluate causality, we performed a 2-sample Mendelian randomization.

RESULTS

In the retrospective study, compared to former users, less than monthly (OR, 1.01; 95% CI, 0.87-1.18;  = 0.87) and monthly cannabis users (OR, 1.15; 95% CI, 0.86-1.52;  = 0.33) did not have higher CKD odds. Conversely, weekly (OR, 1.28; 95% CI, 1.01-1.60;  = 0.04) and daily use (OR, 1.25; 95% CI, 1.04-1.50;  = 0.02) was significantly associated with CKD, adjusted for multiple confounders. In Mendelian randomization, genetic liability to cannabis use disorder was not associated with increased odds for CKD (OR, 1.00; 95% CI, 0.99-1.01;  = 0.96). These results were robust across different Mendelian randomization techniques and multiple kidney traits.

LIMITATIONS

Likely underreporting of cannabis use. In Mendelian randomization, genetic instruments were identified in the GWAS that included individuals primarily of European ancestry.

CONCLUSIONS

Despite the epidemiological association between cannabis use and CKD, there was no evidence of a causal effect, indicating confounding in observational studies.

摘要

原理与目的

大麻使用与慢性肾脏病(CKD)之间的关联存在争议。我们旨在通过一项大型队列研究评估CKD与大麻使用之间的关联,然后使用全基因组关联研究(GWAS)的孟德尔随机化方法评估因果关系。

研究设计

回顾性队列研究和全基因组关联研究。

设置与参与者

回顾性研究在“我们所有人”队列(N = 223,354)中进行。从3项GWAS中确定了大麻使用障碍的遗传工具:精神基因组学联盟物质使用障碍研究、iPSYCH研究和deCODE研究(N = 384,032)。在CKDGen GWAS(N>120万)中研究了遗传工具与CKD之间的关联。

暴露因素

大麻消费。

结局指标

CKD结局包括:基于胱抑素C和肌酐的肾功能、蛋白尿和血尿素氮。

分析方法

我们进行了关联分析,以检验大麻使用频率与CKD之间的关系。为了评估因果关系,我们进行了两样本孟德尔随机化分析。

结果

在回顾性研究中,与既往使用者相比,每月使用少于一次(OR,1.01;95%CI,0.87 - 1.18;P = 0.87)和每月使用一次的大麻使用者(OR,1.15;95%CI,0.86 - 1.52;P = 0.33)的CKD患病几率并未更高。相反,每周使用(OR,1.28;95%CI,1.01 - 1.60;P = 0.04)和每天使用(OR,1.25;95%CI,1.04 - 1.50;P = 0.02)与CKD显著相关,对多个混杂因素进行了校正。在孟德尔随机化分析中,大麻使用障碍的遗传易感性与CKD患病几率增加无关(OR,1.00;95%CI,0.99 - 1.01;P = 0.96)。这些结果在不同的孟德尔随机化技术和多个肾脏特征中均具有稳健性。

局限性

大麻使用情况可能报告不足。在孟德尔随机化分析中,遗传工具是在主要包括欧洲血统个体的GWAS中确定的。

结论

尽管大麻使用与CKD之间存在流行病学关联,但没有因果效应的证据,这表明观察性研究中存在混杂因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1528/9879977/e6fde3eecb76/fx1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验